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ABSTRACT: Weak noncovalent interactions are the basic
forces in crystal engineering. Polymorphism in flexible
molecules is very common, leading to the development of
the crystals of same organic compounds with different
medicinal and material properties. Crystallization of 2,2′-
{[1,2-phenylenebis(methylene)]bis(sulfanediyl)}bis(4,6-dime-
thylnicotinonitrile) by evaporation at room temperature from
ethyl acetate and hexane and from methanol and ethyl acetate
gave stable polymorphs 4a and 4b, respectively, while in acetic
acid, it gave metastable polymorph 4c. The polymorphic
behavior of the compound has been visualized through single-
crystal X-ray and Hirshfeld analysis. These polymorphs are
tested for anti-inflammatory activity via the complete Freund’s adjuvant-induced rat paw model, and compounds have exhibited
moderate activities. Studies of docking in the catalytic site of cyclooxygenase-2 were used to identify potential anti-inflammatory
lead compounds. These results suggest that the supramolecular aggregate structure, which is formed in solution, influences the
solid state structure and the biological activity obtained upon crystallization.
1. INTRODUCTION
Crystal polymorphism, which represents the ability of
molecules to crystallize in more than one conformation
displaying different physical and chemical properties, is of
paramount importance in different fields such as pharmacy,
solid state chemistry, and materials science.1−5 It is well
documented that polymorphism reveals the differences in
pharmaceutically relevant properties, such as hygroscopicity,
stability, solubility, dissolution rates, bioavailability, and some-
times biological activities.6−8 According to Ostwald’s rule of
stages, polymorphs arise by emulative crystallization and
development of metastable to stable polymorphic structures.9,10
Once a metastable domain is encountered, kinetic pathways
determine which form will crystallize.11,12 The possibility of the
establishment of noncovalent attractive interactions involving
sulfur atoms from one side and oxygen or nitrogen atoms from
the other has long been recognized.13-15 These interactions play
an important role in governing properties like spectroscopic
behavior and chemical reactivity. In medicinal chemistry, special
attention has been paid to the influence of such nonbonded
interactions on the design of new drug candidates.16
Hydrogen bonding, CH···π, S···π,17 and π−π, are important
adhesive and cohesive forces in the crystallization of small
aromatic molecules, which occurs between a soft acid and a soft
base.18,19 These interactions undoubtedly play important roles
in determining the conformation of such molecules,20 crystal
packing,21 the assembly of molecules into an organized
supramolecular structure,22 and the structure of proteins and
DNA.23
Several examples of organosulfur compounds are known,
whose conformations, geometries, and biological activity are
influenced by intramolecular nonbonded sulfur−oxygen,
sulfur−nitrogen, or sulfur−sulfur interactions.24,25 In these
molecules, the S···O, S···N, and S···S nonbonded distances are
Received: December 10, 2013
Revised: January 11, 2014
Published: February 11, 2014
Article
pubs.acs.org/crystal
© 2014 American Chemical Society 1347 dx.doi.org/10.1021/cg401842y | Cryst. Growth Des. 2014, 14, 1347−1356
significantly shorter than the sum of the corresponding van der
Waals radii (3.32, 3.35, and 3.60 Å, respectively).
This work deals with the synthesis and development of
polymorphs of the experimental flexible molecule 2,2′-{[1,2-
phenylenebis(methylene)]bis(sulfanediyl)}bis(4,6-dimethylni-
cotinonitrile) (4). The impact of different polymorphs of 4 on
the cyclooxygenase-2 (COX-2) receptor is experimentally
justified by the evaluation of their anti-inflammatory activities.
The different polymorphs were generated on the grounds of
the difference in the polarity of solvents and the rate of cooling
of the solution or evaporation of the solvent.
The synthesis of title compound 4 (Scheme 1) was
conducted by first synthesizing 4,6-dimethyl-2-thioxo-1,2-
dihydropyridine-3-carbonitrile (3) by a general experimental
procedure involving SN2 reactions at room temperature. For
the synthesis of compound 3, 4,6-dimethyl-2-oxo-1,2-dihydro-
pyridine-3-carbonitrile (1) has been synthesized by the reaction
of acetyl acetone and cyanoacetamide in an aqueous ethanolic
solution of potassium carbonate. 2-Chloro-4,6-dimethylnicoti-
nonitrile (2) has been synthesized from the reaction of
phosphoryl chloride with compound 1,26 which upon reaction
with sodium sulfide in dimethylformamide (DMF) at room
temperature in 5 h afforded compound 3.27 Compound 3 upon
reaction with 1,2-bis(bromomethyl)benzene (0.5 equiv) in




2.1. General Procedures. All reactions were monitored by thin
layer chromatography (TLC) over silica gel G UV active plates. The
melting points were recorded on an electrically heated block and are
uncorrected. Infrared data were recorded as KBr discs on an Excalibur
Series Bio-Rad Merlin FTS 3000 spectrophotometer. Nuclear
magnetic resonance (NMR) spectra were recorded on Bruker Avance
300 MHz FT spectrometers equipped with a 5 mm dual probe and a 6
mm multinuclear inverse probe head with a Z-shielded gradient using
TMS as an internal reference [chemical shift in δ (parts per million)].
Mass spectra of the compounds were recorded with a Jeol-JMS-D-300
instrument. Microanalysis was conducted on a Perkin-Elmer PE 2400
CHN elemental analyzer for dried samples.
2.2. Synthesis of 2,2′-{[1,2-Phenylenebis(methylene)]bis-
(sulfanediyl)}bis(4,6-dimethylnicotinonitrile) (4). In a 100 mL
round-bottom flask, compound 3 (0.5 g, 0.003 mol) was dissolved in
dry DMF and the mixture stirred for 15 min. Anhydrous potassium
carbonate (0.46 g, 0.003 mol) was added and the mixture stirred for 2
h. 1,2-Bis-bromomethyl-benzene (0.44 g, 0.002 mol) was added to the
mixture and left to stir for 20 h. Completion of the reaction was
monitored via TLC. DMF was removed through a rotary evaporator,
and ice-cold water was added. Precipitates appeared and were filtered
with a Buchner funnel. The compound was recrystallized, which
yielded an almost pure product: mp 236 °C; yield 0.8 g (67%); 1H
NMR (CDCl3, 300 MHz) δ 2.41 (s, 6H, CH3), 2.52 (s, 6H, CH3),
4.68 (s, 4H, SCH2), 6.77 (s, 2H, HetArCH), 7.19 (d, 2H, Ar-CH),
7.44 (d, 2H, Ar-CH); 13C NMR (CDCl3, 300 MHz) δ 20.08 (CH3),
24.72 (CH3), 28.90 (SCH2), 29.10 (CH2), 104.93 (CCN), 115.23
(CN), 119.73 (HetArCH), 151.76 (CCH3), 161.37 (CCH3), 161.97
(CSC); IR (KBr, cm−1) 613−870 (C−H bending), 1412−1579 (C
C, aromatic stretching), 2217 (C−N stretching), 2855−2924 (C−H
stretching); FAB MS m/z 430 (M + 1). Elemental analysis for
C24H23N4S2. Calcd: C, 66.94; H, 5.15; N, 13.01. Found: C, 66.89; H,
5.09; N, 12.99.
2.3. Crystallization Experiments. Polymorph 4a. 2,2′-{[1,2-
Phenylenebis(methylene)]bis(sulfanediyl)}bis(4,6-dimethylnicotinoni-
trile) was crystallized in a mixture of ethyl acetate and hexane (2:1) by
slow evaporation at room temperature to afford cocrystal 4a.
Polymorph 4b. Again, 2,2′-{[1,2-phenylenebis(methylene)]bis-
(sulfanediyl)}bis(4,6-dimethylnicotinonitrile) was crystallized in a
mixture of methanol and ethyl acetate (2:0.5) by slow evaporation
at room temperature to afford cocrystal 3b, having slight differences in
bond angles.
Polymorph 4c. Again, 2,2′-{[1,2-phenylenebis(methylene)]bis-
(sulfanediyl)}bis(4,6-dimethylnicotinonitrile) was crystallized in a
mixture of acetic acid by slow evaporation at room temperature to
afford cocrystal 3c, having more differences in bond angles.
Scheme 1. Synthesis of 2,2′-{[1,2-
Phenylenebis(methylene)]bis(sulfanediyl)}bis(4,6-
dimethylnicotinonitrile) (4)
Figure 1. ORTEP drawing of the polymorphs of 2,2′-{[1,2-phenylenebis(methylene)]bis(sulfanediyl)}bis(4,6-dimethylnicotinonitrile) in different
solvents: 4a from ethyl acetate and hexane (2:1), 4b from methanol and ethyl acetate (2:0.5), and 4c from acetic acid at 50% thermal ellipsoid
probabilities.
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2.4. X-ray Crystallography. Single-crystal X-ray data, space
groups, unit cell dimensions, and intensity data for 4a−4c were
collected with an Oxford Diffraction X-calibur CCD diffractometer
using graphite monochromated Mo Kα radiation (λ = 0.71073 Å). The
structures were determined by direct methods using SHELXS-9728
and refined on F2 by a full-matrix least-squares technique using
SHELXL-97. Non-hydrogen atoms were refined anisotropically, and
hydrogen atoms were geometrically fixed with thermal parameters
equivalent to 1.2 times that of the atom to which they are bonded.
Molecular diagrams (Figure 1) for all polymorphs were prepared using
ORTEP,29 and the packing diagrams were generated using Mercurry
version 3.1. PLATON30 was used for the analysis of bond lengths,
bond angles, and other geometrical parameters. Hirshfeld surface
analysis was conducted to make quantitative evaluations between
contributions of different noncovalent interactions in polymorphs.31,32
Other crystallographic data are summarized in Table 1.
3. RESULTS AND DISCUSSION
2,2′-{[1,2-Phenylenebis(methylene)]bis(sulfanediyl)}bis(4,6-
dimethylnicotinonitrile) (Figure 2) was crystallized in a mixture
of ethyl acetate and hexane (2:1) by slow evaporation at room
temperature and yielded good quality crystals (4a). Another
polymorph, 4b, was crystallized in a mixture of methanol and
ethyl acetate (2:0.5) by slow evaporation at room temperature,
having slight differences in bond angles. Polymorph 4c was
crystallized in acetic acid, resulting in two conformations with
different symmetry elements.
Polymorph 4a crystallized in the P21/n monoclinic space
group with the following values: a = 10.667(2) Å, b =
18.767(4)Å, c = 11.252(2) Å, β = 93.53(3)°, Z = 4, and V =
2248.1(8) Å. Polymorph 4b crystallized in the P21/n monoclinic
space group with the following values: a = 10.6469(10) Å, b =
18.7554(17) Å, c = 11.2374(10) Å, β = 93.539(2)°, Z = 4, and
V = 2239.6(8) Å. In both polymorphs 4a and 4b, there is slight
difference in bond angles and bond lengths. Polymorph 4c
crystallized in the P21/c monoclinic space group with the
following values: a = 15.815(3) Å, b = 18.657(4) Å, c =
14.626(3) Å, β = 92.98(3)°, Z = 8, and V = 4309.8(15) Å
(Table 1).
In polymorphs 4a and 4b, the mean separations between two
stacked pyridine rings are 3.932 and 3.937 Å, respectively. In
the case of polymorph 4c, the mean separations between two
stacked pyridine rings are 3.905 and 3.829 Å (Table 2). In both
polymorphs 4a and 4b, the angles between two 3-cyano, 4,6-
dimethyl-2-thio-nicotinonitrile ring planes are 1.95° and 4.59°,
respectively, whereas in polymorph 4c, the angle between two
types of 3-cyano, 4,6-dimethyl-2-thio-nicotinonitrile ring planes
is 3.16°, as shown in Figure S1 of the Supporting Information.
Intramolecular and intermolecular π−π interactions create
the molecular stability in the parallel conformation. Packing of
the molecule has been stabilized via various weak interactions.
In the packing diagram of polymorph 4a, all 3-cyano, 4,6-
dimethyl-2-thio-nicotinonitrile rings are parallel to each other
because of the presence of intramolecular π···π (3.932 Å) and
intermolecular π···π (3.742 Å) interactions. This arene
interaction is also observed in the packing diagram of
polymorph 4b, while in the packing diagram of polymorph
4c, the parallel motif is stabilized by two types of intramolecular
π···π interactions (3.905 and 3.829 Å) and also by two types of
intermolecular π···π interactions (3.905 and 3.571 Å) .
In crystals 4a−4c, the intramolecular edge to face C−H···π,
C−H···N, and C−H···S groups also stabilized the conformation
of polymorphs 4a and 4b, which have slight differences in their
bond lengths and bond angles. However, intramolecular CH···
N and π···π interactions stabilized the conformation of one of
the conformers in crystal 4c, while the other was stabilized by
S···S interaction along with such interaction as shown in Figure
3. Hirshfeld surface analysis (Figure 4) shows the contributions
of all hydrogens and interactions in polymorphs 4a and 4b are
the same but those in 4c are different because of the different
extents of inter- and intramolecular interactions. The sharp
spikes in the fingerprint plot of 4a and 4b at de = di ≈ 1.1 Å
indicate short π···π interactions in comparison to those of 4c.
Powder X-ray diffraction (XRD) analysis of polymorphs 4a
and 4b reveals that they show the same pattern, while 4c shows
a different pattern that indicates a new polymorph of
compound 2,2 ′-{[1,2-phenylenebis(methylene)]bis-
(sulfanediyl)}bis(4,6-dimethylnicotinonitrile) as shown in
Figure 5.
3.1. Cox-2 In Silico Studies of Polymorphs. Auto Dock
Protocol. First, all bound waters, ligands, and cofactors were
removed from the proteins. The macromolecule was checked
for polar hydrogens; torsion bonds of the inhibitors were
selected and defined. Gasteiger charges were computed, and the
Auto Dock atom types were defined using Auto Dock version
4.2, the graphical user interface of Auto Dock supplied by MGL
Tools.33 The Lamarckian genetic algorithm (LGA), which is
considered one of the best docking methods available in Auto
Dock,34,35 was employed. This algorithm yields superior
docking performance compared to simulated annealing or the










crystal system monoclinic monoclinic monoclinic
space group P21/n P21/n P21/c
unit cell
dimensions
a (Å) 10.667(2) 10.6469(10) 15.815(3)
b (Å) 18.767(4) 18.7554(17) 18.657(4)




V (Å3) 2248.1(8) 2239.68 4309.8(15)
Z 4 4 8
μ (mm) 0.255 0.256 0.266
hkl ranges −12 ≤ h ≤12 −12 ≤ h ≤ 12 −21 ≤ h ≤ 20
−22 ≤ k ≤ 21 −22 ≤ k ≤ 22 −20 ≤ k ≤ 25
−13 ≤ l ≤ 13 −13 ≤ l ≤ 13 −20 ≤ l ≤ 18
R factor (%) 6.02 5.32 5.63
CCDC No. 710839 973582 722257
Figure 2. Molecular structure of 2,2′-{[1,2-phenylenebis(methylene)]-
bis(sulfanediyl)}bis(4,6-dimethylnicotinonitrile).
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simple genetic algorithm and the other search algorithms
available in Auto Dock version 4.0. Second, the three-
dimensional grid boxes were created by the Auto Grid
algorithm to evaluate the binding energies on the macro-
molecule coordinates. The grid maps representing the intact
ligand in the actual docking target site were calculated with
Auto Grid (part of the Auto Dock package). Eventually, cubic
grids encompassed the binding site where the intact ligand was
embedded. Finally, Auto Dock was used to calculate the
binding free energy of a given inhibitor conformation in the
macromolecular structure, while the probable structural
inaccuracies were ignored in the calculations. The search was
extended over the whole receptor protein used as blind
docking. Molecular docking of compounds was conducted in
the COX-2 crystal structure of Protein Data Bank (PDB) entry
3LN1 (2.9 Å resolution). Celecoxib and nimesulide as COX-2
Table 2. Weak Interactions and Intramolecular Atomic Distances in Polymorphic Cocrystals 4a−4c of 2,2′-{[1,2-
Phenylenebis(methylene)]bis(sulfanediyl)}bis(4,6-dimethylnicotinonitrile)
crystal interaction d (Å) D (Å) θ (deg)
4a C24−H24B···S1 0.960(5) 2.814 139.51
C8−H8C···N2 0.960(3) 2.733 163.08
C9−H9B···S2 0.970(4) 3.533 95.11
C7−H7A···π 0.961(5) 3.718 153.77
C7−H7C···N3 0.959(5) 3.791 117.27
π···π (intramolecular) 3.937
π···π (intermolecular) 3.747
C8−H8A···π 0.959(4) 3.47 103.65
C4−H4···π 0.930(4) 3.288 168.20
C24−H24A···π 0.960(7) 3.86 88.01
C24−H24B···π 0.960(5) 3.712 96.92
C6−N2···S2 1.145(5) 3.831 82.05
C16−H16B···N2 0.970(4) 3.368 123.83
C8−H8B···S2 0.960(3) 3.132 155.26
S1···S2 3.666
4b C20−H20A···C9 0.960(4) 2.845 158.95
C22−H22B···S1 0.960(4) 2.855 134.88
C19−H19C···N3 0.960(3) 2.724 162.88
C19−H19B···S2 0.960(3) 3.124 155.23
C22−H22C···N4 0.960(4) 2.772 155.60
C20−H20B···C21 0.960(4) 2.732 88.09
C20−H20C···C21 0.960(4) 2.885 79.24
C23−H23B···C24 0.960(5) 2.735 91.17
S1···S2 3.658
C6−H6B···S2 0.971(3) 3.54 94.75
C13−H13A···S1 0.971(3) 3.622 93.17
C19−H19A···N2 0.960(3) 3.094 126.55
π···π (intramolecular) 3.932
π···π (intermolecular) 3.742
C3−H3···π 0.930(3) 3.280 167.85
C20−H20A···π 0.960(4) 3.705 154.35
C20−H20B···N3 0.960(4) 3.207 101.8
C20−H20C···N3 0.960(4) 3.392 90.39
C20−H20B···N4 0.960(4) 3.294 133.87
C19−H19A···N4 0.960(3) 3.497 105.55
C19−H19B···N4 0.960(3) 3.684 93.75
C19−H19C···N4 0.960(3) 3.812 86.11
C23−H23A···N3 0.959(5) 3.492 149.16
C23−H23B···N4 0.960(5) 3.259 105.17
C23−H23C···N4 0.959(5) 3.571 85.84
C19−H19A···π 0.960(3) 3.456 104.58
C19−H19B···π 0.960(3) 3.779 84.76
C22−H22A···N2 0.960(7) 2.415 77.76
C22−H22B···N2 0.960(4) 3.096 48.12
C22−H22C···N2 0.961(4) 2.934 37.16
C24···S2 2.965
C21···S1 2.972
C22−H22C···S2 0.961(4) 3.872 134.85
C19−H19B···S1 0.960(3) 3.686 111.97
C19−H19C···S1 0.960(3) 3.713 110.05
crystal interaction d (Å) D (Å) θ (deg)
C13−H13A···N2 0.971(3) 2.566 92.06
C13−H13B···N2 0.970(3) 2.72 83.1
C6−H6A···N1 0.970(3) 3.426 50.96
C6−H6B···N1 0.971(3) 2.350 116.35
4c C16−H16A···π 0.991(3) 3.245 147.42
C9−H9A···π 0.990(3) 3.652 87.97
C9−H9B···π 0.991(2) 3.082 125.90
C33−H33A···π 0.990(2) 3.769 87.80
C33−H33B···π 0.991(2) 3.218 123.97
C40−H40A···π 0.990(2) 3.499 134.39
S1···S2 3.551
S3···S4 3.736
C9−H9A···N1 0.990(3) 3.333 56.31
C9−H9B···N1 0.991(2) 2.364 113.37
C16−H16A···N3 0.991(3) 2.472 99.42
C16−H16B···N3 0.990(3) 2.896 75.12
C33−H33A···N5 0.990(2) 2.750 84.52
C33−H33B···N5 0.991(2) 2.677 88.68
C40−H40A···N7 0.990(2) 2.322 117.00
C40−H40B···N7 0.989(2) 3.490 47.06
N1···S2 3.733
N7···S3 3.681
C8−H8A···N3 0.980(2) 3.087 135.47
C48−H48B···N5 0.980(2) 3.855 69.81
C48−H48C···N5 0.980(2) 2.985 124.8
C16−H16A···N1 0.991(3) 3.491 117.97
C9−H9B···N3 0.991(2) 3.875 141.27
C33−H33B···N7 0.991(2) 2.884 131.91
C47−H47C···N6 0.981(2) 3.346 134.60
π···π (intramolecular) 3.905
π···π (intramolecular) 3.829
C16−H16A···S1 0.991(3) 3.846 85.06
C9−H9B···S2 0.991(2) 3.299 98.54
C8−H8A···π 0.980(2) 3.170 116.12
C44−H44···π 0.950(2) 3.873 73.77
C48−H48B···π 0.980(2) 3.793 84.82
C40−H40A···S3 0.990(2) 3.680 92.11
C33−H33B···S4 0.991(2) 3.585 96.02
π···π (intermolecular) 3.905
π···π (intermolecular) 3.571
C40−H40B···N6 0.989(2) 3.523 134.04
C37−H37···N6 0.950(2) 2.679 164.07
C38−H38···N8 0.950(2) 2.831 162.39
C23−H23C···N8 0.980(3) 3.930 111.95
C47−H47B···N4 0.979(3) 3.270 84.90
C24−H24B···S4 0.980(2) 2.952 131.65
C24−H24C···S4 0.981(2) 3.522 91.30
C20−H20···N8 0.949(2) 2.926 154.26
C23−H23B···S1 0.980(3) 3.652 120.12
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Figure 3. Views of the structure of polymorphs of 2,2′-{[1,2-phenylenebis(methylene)]bis(sulfanediyl)}bis(4,6-dimethylnicotinonitrile) (4a) grown
from ethyl acetate and hexane (2:1), 4b grown from methanol and ethyl acetate (2:0.5), and 4c grown from acetic acid along a, b, and c axes.
Hydrogen bonds are represented by broken light green lines. Carbon atoms are colored red, hydrogen atoms green, sulfur atoms orange, and
nitrogen atoms blue.
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Figure 4. continued
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selective drugs (native ligand) in the crystal structure were also
docked as references. Table 3 shows the docking scores of
polymorphs 4a−4c within the active sites of COX-2 (Figure
6a). From the docking score, it is apparent that 4b shows a
better binding affinity with COX-2 than 4a and 4c. COX-2 has
the larger active site, which makes it possible for molecules to
fit into the COX-2 active site versus the COX-1 channel. The
larger active site of COX-2 is partly due to an additional polar
hydrophilic side pocket compared to that of COX-1. Thus, it is
thought to be a key residue for diaryl heterocycle inhibitors
such as the coxibs. The bulky sulfonamide group in COX-2
inhibitors such as celecoxib prevents the molecule from
entering the COX-1 channel. In celecoxib, the lipophilic pocket
is unavailable by an optionally substituted phenyl ring or a
bulky alkoxy substituent. Within the hydrophilic side pocket of
COX-2, the oxygen of the sulfonamide group forms hydrogen
bonds. The substituted phenyl group at the top of the channel
interacts with the side chains of amino acid residues through
hydrophobic and electrostatic interactions (Figure 6b). The
docking study reveals that compound 4 structurally resembles
celecoxib. Therefore, the anti-inflammatory activity of com-
pound 4 is tested by our in vivo study in rats and compared with
that of the commercial drug nimesulide.
3.2. Biological Activity. Materials and Methods. The
anti-inflammatory activity of compounds was evaluated by the
complete Freund’s adjuvant (CFA)-induced rat paw edema
method. The rat colony was maintained as per norms of the
institutional animal ethical committee, at 25 ± 2 °C under 12 h
light/dark schedules with ad libitum supply of food and water.
Experiments were performed on adult (12−13 weeks) male
rats, weighting 130−150 g. Paw edema was induced by
subcutaneous injection of 100 μL of 1 mg/mL CFA (Sigma-
Aldrich) in the plantar surface of the right hind paws of rats.
Rats were divided into five groups, having five rats in each
group. One group was kept as a control. Group 2 was treated
with the standard NSAID nimesulide. Groups 3−5 were treated
with synthesized compounds 4a−4c, respectively. A single dose
of each drug (10 mg/kg of body weight) was given through
intraperitoneal injection. The dorso-ventral thickness of the
hind paw was measured by using a Vernier caliper placed at the
border of the phalanges and metatarsals. An increase in paw
thickness was compared with that of normal mice. Measure-
ments were taken 2, 6, and 24 h after CFA injection. Each
measurement was repeated three times. The percentage
increase in paw thickness was calculated using the formula [(t
− t0)/t0] × 100, where t0 and t are the thicknesses of the paw
before and after CFA injection, respectively.
The percentage inhibition of swelling was calculated by the
formula (C − T/C) × 100, where C and T are the increases in
the paw thickness of the control and drug-treated groups,
respectively.
Figure 4. Hirshfeld surface two-dimensional fingerprint plots for the different intermolecular interactions in polymorphs 4a−4c of 2,2′-{[1,2-
phenylenebis(methylene)]bis(sulfanediyl)}bis(4,6-dimethylnicotinonitrile).
Figure 5. Powder XRD of crystals 4a−4c.
Table 3. Docking Scores of Polymorphs 4a−4c, Celecoxib,
and Nimesulide with the COX-2 Protein (PDB entry 3LN1)
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Statistical Analysis. The results are expressed as means ±
standard error of the mean (SEM). The data were analyzed
using one-way analysis of variance (ANOVA), followed by
Tukey’s post hoc test. A p value of <0.05 was considered to be
statistically significant (Figure 7). The percentage increases in
paw thickness at different time intervals (mean ± SEM) are
listed in Table 4.
From the anti-inflammatory activity, it was observed that all
the compounds are ineffective at the 2 h time point. After 6 h,
compounds 4a and 4b showed anti-inflammatory activity
(levels of inhibition of paw edema of 37.12 and 33.10%,
respectively), which was lower than that of the positive control
nimesulide (40.44% inhibition). At 24 h, the anti-inflammatory
activity of 4a and 4b was slightly better (27.54 and 34.92%,
respectively) than that of nimesulide (26.89%). On average, 4a
shows better anti-inflammatory activity than 4b. Compound 4c
does not show anti-inflammatory activity at any time point. The
better activity of these compounds in the late phase may be due
to slow absorption or delayed action of compounds 4a and 4b
compared to that of nimesulide. A pharmacokinetic study is
needed to resolve these issues.
4. CONCLUSION
Hydrogen bonding is important in crystallization. The
stoichiometry of the solvent influenced π-stacking motifs in
2,2′-{[1,2-phenylenebis(methylene)]bis(sulfanediyl)}bis(4,6-
dimethylnicotinonitrile) that make finite and infinite aromatic
stacks. In our studies, it is noted that the crystallization of a
compound in different solvents induces different noncovalent
interactions such as sulfur−sulfur, C−H···π, C−H···N, and C−
H···S interactions and is responsible for the formation of
different polymorphic crystals. Structural investigations of the
relationship between crystallization and novel polymorph
discovery should be interesting given the immense importance
of these solid state substances in the pharmaceutical industry.
This study represents the COX-2 activity of polymorphs 4a−
4c. Among them, 4a and 4b are much more potent with respect
to anti-inflammatory activity, which attracts interest in the
polymorphs for their diverse biological activities such as anti-
inflammatory, anticancer, analgesic, antihypertensive, anti-
histamine, etc. These are matters that need to be resolved
with further experimentation and/or modeling.
■ ASSOCIATED CONTENT
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available free of charge via the Internet at http://pubs.acs.org.
Figure 6. (a) Docked pose of compound 4b within COX-2 (PDB entry 3LN1). (b) Structure−activity relationship of celecoxib and compound 4
with the COX-2 active site.
Figure 7. Effect of synthesized compounds on paw thickness 2, 6, and
24 h after CFA injection. Values are expressed as means ± SEM. An
asterisk indicates a significant difference from the control group at the
p < 0.05 level of significance using a one-way ANOVA followed by
Tukey’s post hoc test.
Table 4. Percentage Increases in Paw Thickness at 2, 6, and 24 h Intervals (mean ± SEM) and Average Levels of Inhibition of
Edema at Different Time Intervals
2 h 6 h 24 h average level of inhibition of edema (%) at different time intervals
control 43.3 ± 0.53 80.45 ± 0.18 95.75 ± 5.16 −
nimesulide 37.3 ± 0.16 47.91 ± 5.76 70 ± 2.041 27.06
4a 39.60 ± 0.18 50.58 ± 1.01 69.38 ± 0.17 24.40
4b 38.22 ± 3.99 53.82 ± 2.03 62.31 ± 5.49 26.58
4c 44.47 ± 1.29 53.92 + 8.62 80.31 ± 4.82 15.45
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